Fecal-Derived Sterilized Postbiotic Composition for Anti-Aging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of large-scale clinical research on the safety and tolerability of non-sterilized fecal microbiota transplant (FMT) in healthy populations, and the efficacy of non-sterilized FMT in treating Clostridioides difficile infections and related conditions has not been adequately examined.
Innovation Solution
A method and composition for a fecal-derived sterilized postbiotic are developed, involving the selection of a dose schedule based on baseline biomarkers of aging, which includes short chain fatty acids like acetic acid, propionic acid, and butyric acid, and other agents configured to regulate aging biomarkers, administered to subjects to analyze anti-aging effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-sterilized FMT is used to treat C. difficile infections, then treatment efficacy is achieved, but safety and tolerability cannot be adequately ensured due to lack of clinical research
Solution Approach 1:
The patent extracts and isolates the beneficial postbiotic components from fecal matter, separating them from potentially harmful live microorganisms. This extraction process allows the therapeutic effects to be retained while eliminating safety risks associated with live bacteria in non-sterilized FMT.
Solution Approach 2:
The patent introduces sterilization as an intermediary process between the source material (feces) and the final therapeutic product. This intermediary step removes live microorganisms while preserving postbiotic molecules, serving as a bridge that maintains efficacy while ensuring safety.
2Productivity
If non-sterilized FMT is introduced rapidly for clinical use, then treatment availability is improved, but adequate examination of efficacy and safety is compromised
Solution Approach 1:
The patent performs preliminary sterilization and characterization of the FMT product before clinical application. By pre-processing the material to remove live microorganisms and identify postbiotic components, the patent enables safer and more controlled clinical use without requiring extensive new safety studies.
3Object-affected harmful factors
If sterilization is applied to FMT to ensure safety, then harmful factors are reduced, but the complexity of the manufacturing process increases
Solution Approach 1:
The patent applies sterilization parameters (heat, pressure, time) to transform the FMT material, changing its physical and biological properties. This parameter-based approach systematically reduces bacterial contamination while preserving postbiotic molecules through controlled processing conditions.
Data Source
AI summary
A composition and a method for analyzing an anti-aging effect of the composition of a fecal derived sterilized postbiotic are disclosed. The method includes obtaining a baseline biomarker of aging measurement, wherein the baseline biomarker of aging measurement includes a biomarker of aging, selecting a dose schedule from a plurality of dose schedules of a composition for a fecal derived sterilized postbiotic as a function of the baseline biomarker of aging measurement, wherein the composition includes a plurality of biological macromolecules including at least a short chain fatty acid, wherein the short chain fatty acid includes acetic acid, propionic acid, and butyric acid and a plurality of agents, wherein the plurality of agents is configured to regulate the biomarker of aging and administering the composition to a subject.